Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Epidemiology and Population Health|March 20, 2025
Utilisation des fluoroquinolones à usage systémique en France entre 2014 et 2023 : une étude à partir des données du Système National des Données de Santé (SNDS)Daniele Saade, Marie Joelle Jabagi, Marion Bertrand, et al.
NEJM Evidence|February 25, 2025
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in InfantsMarie Joelle Jabagi, Jérémie Cohen, Marion Bertrand, et al.
JAMA|December 22, 2025
Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in NewbornsMarie-Joelle Jabagi, Marion Bertrand, Amélie Gabet, et al.
Jac-Antimicrobial Resistance|August 18, 2025
Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization studyDaniele Saade, Marie-Joelle Jabagi, Marion Bertrand, et al.
International Journal of Cancer|July 20, 2020
Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohortMarie Joelle Jabagi, Norbert Vey, Anthony Goncalves, et al.
JAMA Network Open|January 19, 2019
Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in FranceMarie Joelle Jabagi, Norbert Vey, Anthony Goncalves, et al.
Cancers|October 2, 2019
Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast CancerMarie Joelle Jabagi, Anthony Goncalves, Norbert Vey, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 10, 2025
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization StudyNadia Haddy, Hugo Jourdain, David Desplas, et al.
The Lancet Regional Health. Europe|June 29, 2026
Maternal RSVpreF Immunisation Against Infant RSV Hospitalisation: Nationwide Population-Based Effectiveness and Durability StudyMarie-Joelle Jabagi, Marion Bertrand, Amélie Gabet, et al.
Nature Communications|June 25, 2022
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccinesStéphane Le Vu, Marion Bertrand, Marie-Joelle Jabagi, et al.
Pageof 2